$IRD News

Opus Genetics: The Future Lies In The Success Of The AAV Delivery Platform

Leerink Partners Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10

Citizens Maintains Market Outperform on Opus Genetics, Lowers Price Target to $11

Opus Genetics Q1 EPS $(0.75) Misses $(0.14) Estimate, Sales $2.157M Miss $2.931M Estimate

Opus Genetics Announces New Clinical And Preclinical Data From Multiple Programs Presented At Association For Research In Vision And Opthalmology Annual Meeting May 3-7

Opus Genetics' OPGx-LCA5 Program Accepted Into FDA's Rare Disease Evidence Principles Program

Citizens Initiates Coverage On Opus Genetics with Market Outperform Rating, Announces Price Target of $12

Opus Genetics Secures Up To $155M Non-Dilutive Financing From Oberland Capital Plus 1.1M Shares At $4.48 To Advance Inherited Retinal Disease Gene Therapy Pipeline

Opus Genetics Secures Up To $155M Non-Dilutive Financing From Oberland Capital Plus 1.1M Shares At $4.48 To Advance Inherited Retinal Disease Gene Therapy Pipeline

Cantor Fitzgerald Initiates Coverage On Opus Genetics with Overweight Rating, Announces Price Target of $15

Oppenheimer Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10

Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $11

Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $10

Earnings Summary: Opus Genetics Q4

Opus Genetics Q4 EPS $(0.21) Misses $(0.12) Estimate, Sales $3.865M Beat $3.649M Estimate

Where Opus Genetics Stands With Analysts

BTIG Maintains Buy on Opus Genetics, Raises Price Target to $12

Opus Genetics Reveals New Clinical Data From Its Ongoing Phase 1/2 Study Of OPGx-BEST1 Gene Therapy; Sentinel Participant Showed OPGx-BEST1 Was Well Tolerated With No Ocular Inflammation, Treatment-related Adverse Events, Or Dose-limiting Toxicities At Three Months;

The FDA Acceptes Opus Genetics' Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% For Presbyopia, With PDUFA Goal Date Of October 17

Opus Genetics: Asymmetric Upside With LCA5 And BEST1